
Sign up to save your podcasts
Or


😴💊 Could a pill transform the treatment of obstructive sleep apnea?
The SynAIRgy Phase 3 trial of AD109 (aroxybutynin + atomoxetine) showed significant reductions in apnea–hypopnea index and hypoxic burden in patients unable to tolerate CPAP therapy. 🌙🫁
A once-nightly oral therapy targeting upper airway neuromuscular dysfunction may represent a new frontier in sleep medicine. Fascinating data with important implications for cardiovascular and metabolic health. 🫀📊
#SleepApnea #OSA #AD109 #SleepMedicine #RespiratoryMedicine #MedicalPodcasts #ClinicalTrials #PrecisionMedicine
By Dr RR Baliga, MD, MBA5
66 ratings
😴💊 Could a pill transform the treatment of obstructive sleep apnea?
The SynAIRgy Phase 3 trial of AD109 (aroxybutynin + atomoxetine) showed significant reductions in apnea–hypopnea index and hypoxic burden in patients unable to tolerate CPAP therapy. 🌙🫁
A once-nightly oral therapy targeting upper airway neuromuscular dysfunction may represent a new frontier in sleep medicine. Fascinating data with important implications for cardiovascular and metabolic health. 🫀📊
#SleepApnea #OSA #AD109 #SleepMedicine #RespiratoryMedicine #MedicalPodcasts #ClinicalTrials #PrecisionMedicine

906 Listeners

3,374 Listeners

20,222 Listeners